They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025
AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Subscribe To Our Newsletter & Stay Updated
Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants
Implementing a digital transformation in chemical operations to maximize profitability
The complexity of compliance
The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation
The guiding role of fluidized and spouted bed technologies in particle building processes
